Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.
Overview
Neuronetics Inc. (NASDAQ: STIM) is a commercial stage medical technology company that focuses on designing, developing and marketing innovative, noninvasive treatments for mental health and neurohealth disorders. At the heart of its portfolio is the NeuroStar Advanced Therapy System, a revolutionary transcranial magnetic stimulation (TMS) platform that utilizes MRI-strength magnetic field pulses to stimulate targeted regions in the brain. This technology is engineered to serve patients with major depressive disorder (MDD) and other psychiatric conditions, particularly for those who have not experienced satisfactory results with traditional pharmaceutical treatments.
Core Technology and Treatment Modality
Neuronetics has established its reputation by pioneering non-drug, noninvasive therapeutic solutions that redefine patient care in the mental health space. The NeuroStar Advanced Therapy System, cleared by the FDA, is designed to generate pulsed magnetic fields to induce controlled electrical currents in focus areas of the brain. This precise approach not only offers an alternative to systemic medications but also addresses the limitations of conventional treatment methods. The company’s emphasis on robust clinical data and the world’s largest depression outcomes registry reinforces its position as an authority in TMS therapy.
Business Model and Operational Focus
The primary revenue streams for Neuronetics are derived from sales of its NeuroStar system and the associated treatment sessions delivered in a clinical setting. Additionally, the company supports a network of treatment centers that provide these services, thereby integrating technology with operational excellence in patient care. By providing comprehensive clinical training and standardizing best practices through initiatives like its Better Me Provider program, Neuronetics ensures consistent treatment quality. Its business strategy is underpinned by a commitment to continuously engage with payors, healthcare providers and policy makers to expand access to TMS therapy.
Market Position and Competitive Differentiation
Neuronetics occupies a distinct niche in the growing field of neurostimulation devices. Its status as the first company to obtain FDA clearance for a noninvasive TMS device specifically indicated for patients who have not benefited from previous antidepressant medications sets it apart in a competitive market. The company’s dedication to research-driven innovation, combined with its extensive clinical adoption, reinforces its credibility among medical professionals and investors alike. Furthermore, recent strategic mergers have enhanced its operational scale, creating a vertically integrated organization that fosters consistent delivery of standardized best practices across treatment sites.
Clinical Impact and Research Excellence
At the core of Neuronetics’ approach is a commitment to improving patient outcomes. Its NeuroStar Advanced Therapy System has been validated by a significant clinical data set, establishing strong response and remission rates among patients with MDD. The system is also cleared for use in adolescent populations, addressing the critical need for early intervention in mental health care. Neuronetics continues to invest in research and development to assess the full spectrum of benefits associated with TMS therapy, thereby deepening the clinical understanding of treatment efficacy and safety.
Industry Expertise and Authoritativeness
With a dedicated team specialized in health policy advocacy and clinical education, Neuronetics bridges the gap between innovative technology and evidence-based mental health care. The firm’s ability to collaborate with both commercial and government payors to expand insurance coverage for TMS treatments showcases its expertise and strategic foresight. Its work is consistently informed by high-quality clinical research and real-world evidence, making it a trusted source of innovative mental health solutions.
Summary
In summary, Neuronetics stands out in the medical device industry by combining cutting-edge TMS technology with a patient-centric approach to mental health care. Its NeuroStar Advanced Therapy System offers a noninvasive, clinical alternative for those with depression and anxiety, backed by extensive clinical validation. Through its integrated network of treatment centers, robust clinical data and strategic collaborations, Neuronetics reinforces its authority in the neurostimulation space and continues to shape the landscape of mental health treatment.
Neuronetics, a medical technology company listed on NASDAQ as STIM, announced the granting of 69,758 Restricted Stock Units (RSUs) to ten new non-executive employees as part of their inducement to join the company. The RSUs vest in three equal installments over three years, contingent on continued employment. This move follows NASDAQ Listing Rule 5635(c)(4) and aims to enhance talent retention and attract skilled professionals in their field. Neuronetics focuses on neurohealth technologies, notably the NeuroStar system for treating mental health disorders.
Neuronetics, Inc. (NASDAQ: STIM) reported a 20% increase in Q3 2022 revenue, totaling $16.5 million, compared to $13.8 million in Q3 2021. The U.S. treatment session revenue reached a record $11.9 million, with a 51% rise in NeuroStar System revenue. The company raised its full-year revenue guidance to $63-64 million. Positive regulatory updates include FDA clearance for the D-Tect™ MT Accessory, and multiple TMS coverage policies improving patient access. However, operating expenses increased by 14.6% to $20.4 million, with a net loss of $(7.6) million, slightly better than the previous year.
Neuronetics, Inc. (NASDAQ: STIM) has been awarded the 2022 bronze medal in the HealthTech category by the Merit Awards for its NeuroStar Advanced Therapy, a notable innovation in mental health treatment.
NeuroStar offers a non-drug solution for psychiatric disorders, particularly depression. Over 4.8 million treatments have been delivered, supported by extensive clinical data. CEO Keith J. Sullivan emphasized the company's commitment to improving patient lives and continuing innovation in neurohealth.
MALVERN, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) plans to release its Q3 2022 financial results on November 8, 2022, prior to market open. A conference call will follow at 8:30 a.m. ET to discuss the results, with a live webcast available. Neuronetics focuses on improving mental health through its NeuroStar Advanced Therapy, a non-invasive treatment for mood disorders like major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). NeuroStar has delivered over 4.8 million treatments and is backed by extensive clinical data.
Neuronetics (NASDAQ: STIM) has announced updates to its TrakStar platform to improve the patient management experience for NeuroStar providers. These enhancements streamline patient identification and re-treatment processes, supporting clinicians in managing treatment for drug-resistant depression. The upgrades include a simplified interface, automated patient candidate generation through the PHQ-10 tool, and improved benefits investigation integration. This marks the third enhancement of the TrakStar platform in 2022, reflecting Neuronetics’ ongoing commitment to innovation and support for mental health treatment.
Neuronetics announced the grand opening of NeuroStar University in Charlotte, North Carolina, the first training center in the TMS industry aimed at enhancing best practices for mental health treatment.
This facility will provide comprehensive education to help practices deliver optimal outcomes with NeuroStar Advanced Therapy. The curriculum includes Learn, Connect, and Grow components to enhance treatment quality for patients with drug-resistant depression.
Currently, NeuroStar University offers free two-day classes for existing practices.
Neuronetics, Inc. (NASDAQ: STIM) has granted inducement awards to 12 new non-executive employees, complying with NASDAQ Listing Rule 5635(c)(4). A total of 55,680 Restricted Stock Units (RSUs) were awarded, with vesting occurring in three equal installments over three years, contingent on continued service. The RSUs are part of the Neuronetics 2020 Inducement Plan. As a leader in neuroscience and TMS treatment, Neuronetics aims to enhance life quality for those with neurohealth disorders, including major depressive disorder.
Neuronetics (NASDAQ: STIM) reported Q2 2022 revenue of $16.3 million, exceeding guidance of $15.0 million to $16.0 million. This marks a 15% increase from Q2 2021, driven by a 70% rise in NeuroStar System sales, achieving a record 59 systems sold. Operationally, the company secured FDA clearance for treating OCD and anxious depression, and forged a long-term partnership with Alleviant Health Centers. However, net loss rose to $10.4 million, and international revenues fell by 50%. For 2022, revenue guidance is set between $60.0 million and $62.0 million.
MALVERN, Pa., July 28, 2022 - Neuronetics (NASDAQ: STIM), a medical technology company, will present at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 11:30 am ET. CEO Keith Sullivan and CFO Steve Furlong will lead the presentation, which will be available via a live audio webcast on the company's investor relations page. Neuronetics, known for its NeuroStar® Advanced Therapy system, specializes in treatments for neurological disorders and aims to enhance life quality for patients with mental health conditions through innovative, FDA-cleared solutions.
Neuronetics (NASDAQ: STIM) announced a partnership with Alleviant Health Centers to expand access to its NeuroStar Advanced Therapy for mental health. This agreement makes Neuronetics the exclusive supplier of transcranial magnetic stimulation (TMS) equipment to Alleviant, with six NeuroStar systems to be delivered in 2022. NeuroStar, a proven non-drug treatment for major depressive disorder (MDD), has delivered over 4.5 million treatments with an 83% response rate. Alleviant aims to enhance patient care by upgrading its TMS devices, highlighting the synergy in improving mental health treatment.
FAQ
What is the current stock price of Neuronetics (STIM)?
What is the market cap of Neuronetics (STIM)?
What does Neuronetics Inc. specialize in?
How does the NeuroStar Advanced Therapy System work?
What makes Neuronetics different from other medical device companies?
Who are the primary patients for NeuroStar therapy?
How does Neuronetics generate revenue?
What role does clinical research play in Neuronetics' strategy?
How does Neuronetics collaborate with healthcare providers?
